

## Vetenskapliga publikationer (uppdaterad 260116)

1. Naeser Y, Mikiver R, Isaksson K, Lambe M, Ullenhag G. Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study. *Int J Cancer* 2025 Dec 12. doi: 10.1002/ijc.70287. Online ahead of print.
2. Marjanovic M, Mikiver R, Nielsen K, Isaksson K, Claeson M. Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden. *Br J Dermatol* 2025 Nov 26:ljaf478.doi: 10.1093/bjd/ljaf478. Online ahead of print.
3. Yu WY, Pazhava A, Weitemeyer MB, Hölmich LR, Johansson I, Olofsson Bagge R, Utikal J, Venna S, Jackson J, Amaral T, van Akkooi A, Kolodney MS, McArthur GA, Meves A. CP-GEP Identifies High-Risk T1a Melanoma Patients Beyond Established Adverse Features. *J Am Acad Dermatol*. 2025 Oct 13:S0190-9622(25)03004-X.
4. Stassen RC, Maas CCHM, Leong SP, Kashani-Sabet M, White RL, Pockaj BA, Zager JS, Schneebaum S, Vetto JT, Avisar E, Harrison Howard J, O'Donoghue C, Kosiorek H, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ, Olofsson Bagge R. External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy. *Br J Surg*. 2025 Mar 28;112(4):znaf037.
5. Lo SN, Gjorup C, Chakera AH, Hölmich LR, Moncrieff M, MacKenzie Ross A, Cassell O, Ma J, Weitemeyer MB, Olofsson Bagge R, Klausen S, Calsavara VF, Duprat Neto JP, Bertolli E, Ch'ng S, Saw RPM, Shannon KF, Spillane AJ, Nieweg OE, Stretch JR, Mann GJ, Geh JLC, Haydu LE, Martin RCW, Sharon C, Karakousis GC, Kashani-Sabet M, Adigbli G, El Sharouni MA, Gershenwald JE, Scolyer RA, Thompson JF, Varey AHR. Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma. *JAMA Dermatol*. 2025 Jun 1;161(6):589-596. doi: 10.1001/jamadermatol.2025.0318.
6. Huibers A, Leong SP, Kashani-Sabet M, White RL Jr, Vetto J, Schneebaum S, O'Donoghue C, Howard H, Avisar E, Namm JP, Kosiorek H, Faries M, Karakousis G, Zager JS, Olofsson Bagge R; on behalf of the Sentinel Lymph Node Working Group. Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma. *Ann Surg Oncol*. 2025 May;32(5):3203-3211. doi: 10.1245/s10434-025-17084-4.Epub 2025 Mar 10.
7. Morrison SL, Han G, Elenwa F, Leong SP, Kashani-Sabet M, Pockaj B, Kosiorek HE, White RL Jr, Zager JS, Messina JL, Sondak V, O'Donoghue C, Howard JH, Schneebaum S, Olofsson Bagge R, Namm JP, Garberoglio C, Avisar E, Fowler G, Han D, Vetto J; Sentinel Lymph Node Working Group. Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis. *Am J Surg*. 2025 Aug;246:116243. doi: 10.1016/j.amjsurg.2025.1162432025.

8. Riaz N, Huibers A, Leong SP, Kashani-Sabet M, White RL Jr, Vetto JT, Schneebaum S, O'Donoghue C, Howard H, Avisar E, Namm JP, Kosiorek H, Pockaj B, Faries M, Karakousis G, Zager JS, Olofsson Bagge R. Prognostic Value of Nevus-Associated Melanoma in Patients with Melanoma. *Ann Surg Oncol*. Epub 2025 Feb 1. doi: 10.1245/s10434-025-16945-2.
9. Girmay Y, Portelli F, Mikiver R, Lapins J, Isaksson K, Helgadottir H. Desmoplastic melanoma in Sweden in 2009–2022: A population-based registry study demonstrating distinctive tumour characteristics, incidence and survival trends. *JEADV* 2025, Epub Jan 8. doi: 10.1111/jdv.20522
10. DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters MWJM, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, Olofsson Bagge R, Zager JS. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. *Cancer*. 2024 Nov  
10.https://doi.org/10.1002/cncr.35636
11. Helgadottir H, Mikiver R, Schultz K, Nielsen K, Portelli F, Lapins J, Puig S, Isaksson K. Melanoma Incidence and Mortality Trends Among Patients Aged 59 Years or Younger in Sweden. *JAMA Dermatol*. 2024;160(11):1201-1210
12. Olofsson Bagge R, Mikiver R, Marchetti MA, Lo SN, van Akkooi ACJ, Coit DG, Ingvar C, Isaksson K, Scolyer RA, Thompson JF, Varey AHR, Wong SL, Lyth J, Bartlett EK. Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. *JAMA Surg*. 2024;159:260-268
13. Helkkula T, Christensen G, Mikiver R, Ingvar Å, Isaksson K, Nielsen K. Acral Melanoma Incidence and Survival Trends in 1990-2020: A Nationwide, Population-based Study. *Acta Derm Venereol*. 2024 Aug 14;104:adv40242.
14. Helgadottir H, Ny L, Ullenhag G, Falkenius J, Mikiver R, Olofsson Bagge R, Isaksson K. Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study. *J Natl Cancer Inst* 2023;115(9):1077-84
15. Naeser Y, Mikiver R, Ingvar C, Lambe M, Ullenhag G. Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study. *EClinicalMedicine* 2023;65:102284
16. Vikström S, Mikiver R, Lapins J, Nielsen K, Vassilaki I, Lyth J, Isaksson K, Eriksson H. Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden. *Br J Dermatol*. 2023;189(6):702-709.

17. Lyth J, Mikiver R, Nielsen K, Ingvar C, Olofsson Bagge R, Isaksson K. Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival - An ideal tool for individualised treatment decisions for Swedish patients. *Eur J Surg Oncol*. 2023;49(10):106974
18. Holmberg CJ, Mikiver R, Isaksson K, Ingvar C, Moncrieff M, Nielsen K, Ny L, Lyth J, Olofsson Bagge R. Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm). *Ann Surg Oncol*. 2023;30(13):8026-8033.
19. Krakowski I, Häbel H, Nielsen K, Ingvar C, Andersson T, Girnita A, Smedby K, Eriksson H. Association of metformin use and survival in patients with cutaneous melanoma and diabetes. *Br J Dermatol*. 2023;188(1):32-40
20. M Moncrieff, S Lo, R Scolyer, M Heaton, J Nobes, A Snelling, R Olofsson Bagge ... J Zager. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. *J Clin Oncol*. 2022;40(34):3940-3951.
21. E Mulder, I Johansson, D Grünhagen, D Tempel, B Rentroia-Pacheco, J Dwarkasing,...R Olofsson Bagge. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse. *Cancers* 2022;14(12):2854
22. CJ Holmberg, L Ny, T Hieken, M Block, M Carr, V Sondak,...R Olofsson Bagge. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study. *Eur J Cancer* 2022;169:210-222
23. I Johansson, D Tempel, J Dwarkasing, B Rentroia-Pacheco, J Mattsson, Ny L, Olofsson Bagge R. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. *Eur J Surg Oncol*. 2022;48(2):320-325
24. H Eriksson, K Nielsen, I Vassilaki, J Lapins, R Mikiver, J Lyth, K Isaksson Trend Shifts in Age-Specific Incidence for In Situ and Invasive Cutaneous Melanoma in Sweden. *Cancers* 2021;13(11):2838.
25. R Kiffin, J Johansson, R Olofsson Bagge, A Martner. Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma. *Eur J Surg Oncol* 2021;47:2460-2464
26. KK Broman, T Hughes, L Dossett, J Sun, D Kirichenko, MJ Carr, ...R Olofsson Bagge...Active surveillance of patients who have sentinel node positive melanoma: an international, multi-institutional evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT 2). *Cancer* 2021;127:2251-2261

27. KK Broman, TM Hughes, LA Dossett, J Sun, MJ Carr, DA Kirichenko, ...R Olofsson Bagge. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. *J Am Coll Surg* 2021;232:424-431
28. R Olofsson Bagge, L Ny, PA Ascierto, FS Hodi, J Larkin, C Robert et al. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. *Melanoma Res* 2021;31:181-185
29. MD Moncrieff, S Lo, R Scolyer, J Nobes, M Heaton, ...R Olofsson Bagge. A quest for the lost tribe: Surgical management of AJCC IB melanoma with the advent of adjuvant systemic therapy. *Ann Surg Onc* 2021;28 (suppl 1):27
30. D Gyorki, MD Moncrieff, RP Saw, AJ Spillane, R Olofsson Bagge, F Wright et al. Melanoma Margins Trial (MelMarT-II): A framework for global recruitment to a large multicentre multinational randomized controlled trial. *Ann Surg Onc* 2021;28(suppl 1):105
31. H Eriksson, D Utjés, R Olofsson Bagge, P Gillgren, K Isaksson, J Lapins et al. The proportion cured of patients with resectable stage II-III cutaneous melanoma in Sweden. *Cancers* 2021;13:2456
32. H Helgadottir, K Isaksson, I Fritz, C Ingvar, J Lapins, V Höiom et al. Multiple primary melanoma incidence trends over five decades: a nationwide population-based study. *J Natl Cancer Inst* 2021;113(3):318-328
33. K Isaksson, R Mikiver, H Eriksson, J Lapins, K Nielsen, C Ingvar, J Lyth. Survival in 31 670 patients with thin melanomas: a Swedish population-based study *Br J Dermatol* 2021;184 (1):60-67
34. A Sanna, K Harbst, I Johansson, G Christensen, M Lauss, S Mitra, ..C Ingvar, G Jönsson. Tumor genetic heterogeneity analysis of chronic sun-damaged melanoma. *Pigment Cell Melanoma Res* 2020;33:480-489
35. D Katsarelias, H Eriksson, R Mikiver, I Krakowski, JA Nilsson, L Ny, R Olofsson Bagge. The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma—A Nation-Wide Swedish Population-Based Retrospective Register Study. *Cancers* 2020;12(11),3228
36. S Mitra, M Lauss, R Cabrita, J Choi, T Zhang, K Isaksson et al. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. *Molecular Oncology* 2020;14:933-950
37. I Fritz, P Wagner, M Bottai, H Eriksson, C Ingvar, I Krakowski, K Nielsen, ... Desloratadine and loratadine use associated with improved melanoma survival. *Allergy* 2020;75:2096-2099

38. R Cabrita, S Mitra, A Sanna, H Ekedahl, K Lövgren, H Olsson, C Ingvar, ...  
The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. *Cancers* 2020;12:742
39. Å Ingvar, H Olsson, P Broberg, K Isaksson, C Ingvar, K Nielsen  
Participation in a Prospective Cohort Study on Melanoma did not Affect the Incidence and Mortality of the Studied Disease. *Acta Derm Venereol* 2020;100 (1), 1-6
40. Tufvesson Stiller H, Mikiver R, Uppugunduri S, Lindholm C, Månsson-Brahme E, Schmitt-Egenolf M. Health Related Quality of Life in Melanoma Patients – characterization of a Swedish cohort. *Br J Dermatol* 2020;182:506-508.
41. D Utjés, J Malmstedt, J Teras, K Drzewiecki, HP Gullestad, C Ingvar et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. *Lancet* 2019;394:471-477
42. Corderfeldt A, Nielsen S, Katsarelias D, Hjärpe A, Mattsson J, Olofsson Bagge R. Is blood a necessary component of the perfusate during isolated limb perfusion – a randomized controlled trial. *Int J Hyperthermia*. 2019; 36(1):794-800.
43. Belgrano V, Mattsson J, Nilsson J, Olofsson Bagge R, Katsarelias D. BRAF status as a predictive factor for response in isolated limb perfusion. *Int J Hyperthermia*. 2019;36(1):511-515.
44. Belgrano V, Pettersson J, Nilsson JA, Mattsson J, Katsarelias D, Olofsson Bagge R. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients with In-Transit Metastases of Malignant Melanoma. *Ann Surg Oncol*. 2019;26:1055-1062
45. Isaksson K, Katsarelias D, Mikiver R, Carneiro A, Ny L, Olofsson Bagge R. A population-based comparison of the AJCC 7th and AJCC 8th Editions for patients diagnosed with stage III cutaneous malignant melanoma in Sweden. *Ann Surg Oncol*. 2019;26(9): 2839-2845.
46. Isaksson K, Mikiver R, Nieveg O, Scolyer R, Thompson JF, Ingvar C. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts. *J Surg Oncol* 2018;118(4):599-605.
47. Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Peach H, Oudit D, Geh J, Dziewulski P, Wilson E, Matteucci P, Pritchard-Jones R, Olofsson Bagge R, Wright FC, Crampton N, Cassell O, Jallali N, Berger A, Kelly J, Hamilton S, Durrani A, Lo S, Paton E, Henderson MA. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. *Ann Surg Oncol*. 2018;25:2541-2549
48. Katsarelias D, Rådbo E, Ben-Shabat I, Mattsson J, Olofsson Bagge R. The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with

In-transit Melanoma Metastases Treated with Isolated Limb Perfusion. *Ann Surg Oncol.* 2018;25:1836-1842

49. Lyth J. Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study. *Melanoma Res.* 2018;28(6):637-40.
50. Ben-Shabat I, Belgrano V, Hansson C, Olofsson Bagge R. The Effect of Perfusate Buffering on Toxicity and Response in Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases. *Int J Hyperthermia* 2017;33:483-488
51. Lyth J, Falk M, Maroti M, Eriksson H, Ingvar C. Prognostic risk factors of first recurrence in patients with primary stage I-II cutaneous malignant melanoma -from the population-based Swedish melanoma register. (ms no. JEADV-2016-2321.R1) *J Eur Acad DermVen* 2017;31:1468-1474.
52. Nyström Wendt A, Mattsson J, Olofsson Bagge R. Myoglobin Does Not Predict Local Toxicity in Isolated Limb Perfusion. *Int J Hyperthermia.* 2017;33(6):679-683.
53. Claeson M, Gillstedt M, Whiteman DC, Paoli J. Lethal Melanomas: A Population-based Registry Study in Western Sweden from 1990 to 2014. *Acta Derm Venereol.* 2017;97:1206-1211.
54. Claeson M, Holmström P, Hallberg S, Gillstedt M, Gonzalez H, Wennberg AM, Paoli J. Multiple Primary Melanomas: A Common Occurrence in Western Sweden. *Acta Derm Venereol.* 2017;97:715-719.
55. Welinder C, Pawlowski K, Makovleva Y, Sugihara Y, Malm J, Jonsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Rezeli M, Laurell T, Wieslander E, Marko Varga G. Correlation of Histopathologic Characteristics to Protein Expression and Function in Malignant Melanoma. *PLoS One* 2017 Apr 26;12(4):e0176167. doi: 10.1371/journal.pone.0176167. eCollection 2017.
56. Hafström A, Silfverschiöld M, Persson SS, Kanne M, Ingvar C, Wahlberg P, Romell A, Greiff L. Benefits of initial CT staging before sentinel lymph node biopsy in patients with head and neck cutaneous melanoma. *Head Neck.* 2017;39:2301-2310.
57. Cirenajwis H, Lauss M, Ekedahl H, Törngren T, Kvist A, Saal LH, Olsson H, Staaf J, Carneiro A, Ingvar C, Harbst K, Hayward NK, Jönsson G. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. *Mol Oncol.* 2017;11(4):438-451.
58. Nielsen K, Lapins J, Lindholm C. Äldre med melanom söker sent och har högre dödlighet - Med ökande kunskap kan trenden brytas – några kliniska särdrag är viktiga att uppmärksamma. *Lakartidningen.* 2017 May 9;114.

59. Ingvar C, Eriksson H. Varannan timme får en svensk ett nytt malignt melanom - Incidens, utfall och prevention. *Lakartidningen*. 2017 May 9;114.
60. Helgadottir H, Tuominen R, Olsson H, Hansson J, Höiom V. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. *J Am Acad Dermatol*. 2017;77:893-901
61. Utjés D, Lyth J, Lapins J, Eriksson H. Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas – a nationwide, population-based study. *Int J Cancer* 2017;141:2243-2252
62. Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P. Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study. *Int J Cancer* 2016;138:2154-2160.
63. Lyth J, Mikiver R, Nielsen K, Isaksson K, Ingvar C. Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register. *Eur J Cancer* 2016; 59: 171-8.
64. Lyth J, Carstensen J, Synnerstad I, Lindholm C. Stage-specific direct health care costs in patients with cutaneous malignant melanoma. *J Eur Acad Dermatol Venereol*. 2016;30(5):789-93.
65. Rockberg J, Amelio JM, Taylor A et al. Epidemiology of cutaneous melanoma in Sweden - stage specific survival and rate of recurrence. *Int J Cancer* 2016;139:2722-2729.
66. Bagge AS, Ben-Shabat I, Belgrano V, Olofsson Bagge R. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion. *Ann Surg Oncol*. 2016;23:2062-9.
67. Dossett LA, Ben-Shabat I, Olofsson Bagge R, Zager JS. Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. *Ann Surg Oncol*. 2016;23:2330-5.
68. Eriksson H, Lyth J, Andersson TM. The proportion cured of patients diagnosed with Stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study. *Int J Cancer* 2016; 138:2829-36.
69. Maroti M, Ulf E, Lyth J, Falkmer U. A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence. *Eur J Dermatol* 2016;26:586-591
70. Simberg-Danell C, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Carstensen J, Hansson J, Eriksson H. Prognostic factors and disease-specific survival among

immigrants diagnosed with cutaneous malignant melanoma in Sweden. *Int J Cancer*. 2016;139:543-53.

71. Hafström A, Romell A, Ingvar C, Wahlberg P, Greiff L. Sentinel lymph node biopsy staging for cutaneous malignant melanoma of the head and neck. *Acta Otolaryngologica* 2016;128:312-318.
72. Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. Use of Phosphodiesterase Type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. *JAMA* 2015;313:2449-2455
73. Krynitz B, Rozell BL, Lyth J, Smedby KE, Lindelof B. Cutaneous malignant melanoma in the Swedish organ transplantation cohort: A study of clinicopathological characteristics and mortality. *J Am Acad Dermatol*. 2015;73(1):106-13 e2.
74. Sundler E, Werner-Hartman L, Ingvar C. Validering av svenska melanomregistret visar liten felregistrering. *Lakartidningen* 2016, volym 113.
75. Eriksson H, Frohm-Nilsson M, Jaras J et al. Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study. *Br J Dermatol*. 2015; 172:175-86.
76. Lyth J, Eriksson H, Hansson J et al. Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men. *Br J Dermatol*. 2015; 172:700-6.
77. Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. *J Clin Oncol*. 2014;32(13):1356-64.
78. Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: A nationwide population-based study in Sweden. *Eur J Cancer*. 2013;49(12):2705-16.
79. Lyth J, Hansson J, Ingvar C, Mansson-Brahme E, Naredi P, Stierner U, Wagenius G, Lindholm C. Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. *Br J Dermatol*. 2013;168 (4):779-86.
80. Lindholm C, Andersson R, Dufmats M, Hansson J, Ingvar C, Moller T, Sjodin H, Stierner U. Invasive cutaneous malignant melanoma in Sweden, 1990-1999 - A prospective, population-based study of survival and prognostic factors. *Cancer-Am Cancer Soc*. 2004;101(9):2067-78.